Turn Therapeutics Secures Up to $25M Debt Facility, Extends Runway for Clinical Programs

summarizeSummary

Turn Therapeutics Inc. secured a new loan and security agreement for up to $25 million, with an initial $7 million funded, to extend its operational runway and advance clinical trials for atopic dermatitis and onychomycosis.

check_boxKey Events

• Secured $25M Loan Facility

  Turn Therapeutics entered into a Loan and Security Agreement for up to $25 million, with an initial $7 million funded immediately.

• Extends Operational Runway

  The financing is expected to extend the company's runway through its Phase 2 atopic dermatitis readout and potentially through the end of 2027 if all tranches are funded.

• Dilutive Equity Components

  The agreement includes an immediate $1.2 million equity grant to the lender and a conversion option for up to $3 million of principal into common stock at 80% of the trading price.

• Asset-Backed Debt with High Interest

  The loan is secured by all company assets, including intellectual property, and carries a minimum annual interest rate of 12.25%.

auto_awesomeAnalysis

Turn Therapeutics Inc. has secured a significant growth capital loan facility of up to $25 million from Avenue Venture Opportunities Fund II, L.P. This financing is critical for the clinical-stage company, providing an immediate $7 million in funding to extend its operational runway and support the advancement of its atopic dermatitis and onychomycosis clinical programs. While the financing ensures continued operations, it comes with substantial costs, including a high minimum annual interest rate of 12.25% and a lien on all company assets, including intellectual property. Additionally, the agreement includes dilutive components: an immediate $1.2 million equity grant to the lender and a conversion option for up to $3 million of outstanding principal into common stock at a discount (80% of the trading price). The availability of subsequent tranches (up to $18 million) is contingent upon achieving specified clinical and financing milestones, introducing future uncertainty but also potential for further capital.